Today, DSM-firmenich released its latest financial report. It posted a strong first-quarter performance, recording sales of €3,274 million, reflecting a 7% year-on-year increase.
CEO Dimitri de Vreeze attributed this solid growth to the effective implementation of the company’s strategic initiatives, particularly cost and revenue synergy programs. He highlighted the group’s ability to deliver innovative solutions across Nutrition, Health, and Beauty segments, which continue to support essential consumer products in a volatile global environment.
The company reaffirmed its full-year 2025 outlook of at least €2.4 billion in Adjusted EBITDA, supported by strong innovation-led growth and a €200 million contribution from internal self-help initiatives.
Within the Perfumery & Beauty division, sales reached €1,015 million, a 3% increase year-over-year. Growth was driven by a standout performance in Perfumery, which achieved high single-digit organic sales growth, led by strong demand in Fine Fragrances, Consumer Fragrances, and Ingredients.
However, the Beauty & Care segment lagged due to weaker sun filter demand and customer destocking, reflecting ongoing softness in the suncare market. Even so, the division reported 2% organic sales growth overall, supported by 3% higher volumes—with volume growth reaching 6% when excluding sun filters.
For the group, we estimate a full-year Adjusted EBITDA of at least €2.4 billion, which now includes an about €150 million contribution from the temporary vitamin price effect from a supply disruption in the vitamin market (of which €85 million was recorded in Q1) and a (pro-rata) deconsolidation effect of about €40 million of Adjusted EBITDA owing to the divestment of the Feed Enzymes business.
